buparvaquone

07/06/2012 - "Buparvaquone is very effective in the treatment of Theileria infections in cattle. "
08/01/1992 - "Buparvaquone, at the dosage evaluated, had transitory therapeutic efficacy against acute B equi infection in splenectomized horses, but was unable alone to clear carrier infection."
05/01/1989 - "Buparvaquone given at the rate of 4 to 6 mg/kg IV and/or IM was therapeutically effective in 4 of 5 acute B equi infections in splenectomized ponies. "
07/17/1998 - "A clinical trial testing the prophylactic effect of a 5 mg kg-1 dose of buparvaquone on either Theileria annulata or Theileria parva experimental infections of calves demonstrated its efficacy for periods of at least seven days. "
08/01/1992 - "We evaluated the efficacy of buparvaquone in eliminating infection with Babesia equi of European origin in carrier horses and in splenectomized horses with experimentally induced acute infection. "

01/01/2008 - "[Therapeutic efficacy of buparvaquone (buparvon) in cattle with theileriosis]."
05/01/1998 - "Buparvaquone (Butalex), a therapeutic for theileriosis, has been shown to have anti-leishmanial activity in vitro. "
01/01/2008 - "The aim of this study was to examine the efficacy of buparvaquone (Buparvon, ALKE, Istanbul) in the treatment of theileriosis in cattle. "
12/01/2022 - "Control of tropical theileriosis, caused by the apicomplexan Theileria annulata, depends on the use of a single drug, buparvaquone, the efficacy of which is compromised by the emergence of resistance. "
07/06/2012 - "The present study reported an outbreak of bovine tropical theileriosis in Fars Province, southern Iran with buparvaquone treatment failure associated with mutations in drug-binding sites of its causative agent. "

07/01/2015 - "The study proposes that buparvaquone may be further investigated as a candidate drug for treatment of cutaneous leishmaniasis."
01/01/2007 - "Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis."
01/01/2007 - "As the part of a study to develop buparvaquone (BPQ) formulations for the treatment of cutaneous leishmaniasis, the topical delivery of BPQ and one of its prodrugs from a range of formulations was evaluated. "
10/15/2020 - "Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis."
01/01/2004 - "In addition, 4b easily released the parent drug in human skin homogenate and, therefore, is a promising prodrug candidate to deliver buparvaquone through the skin for the treatment of cutaneous leishmaniasis."

06/30/2006 - "Thirty-two cattle (56%) received single-dose treatment (2.5 mg buparvaquone per kg body weight), while two and three-dose treatment with interval(s) of 48 h was given to 33% and 11% of total treated cattle, respectively; 38 cattle (60.3%) were treated at an early stage of the disease, while 25 cattle (39.7%) were treated at an advanced stage of the disease. "
05/01/1999 - "Buparvaquone (2.5 mg/kg body weight) was administered to animals in the second group. "
05/01/1989 - "When administered at the rate of 2.5 mg/kg of body weight, IM, 4 times at 96-hour intervals, buparvaquone was effective in eliminating B equi carrier infection in 1 horse. "
09/01/2023 - "Haematological analysis confirmed clinical signs of infection in affected animals, which were treated with buparvaquone @ 2.5 mg/kg body weight intramuscularly along with supportive medicine. "
08/01/1992 - "When administered at the rate of 5 mg/kg of body weight, IV, 4 times at 48-hour intervals, buparvaquone prompted rapid abatement of parasitemia. "

01/01/2018 - "Buparvaquone (BPQ), a hydroxynapthoquinone with in vitro activity in the nanomolar range, failed to clinically translate as a viable treatment for visceral leishmaniasis due to its poor oral bioavailability limited by its poor aqueous solubility (BCS Class II drug). "
01/01/2021 - "Biogenic nanoporous silicon carrier improves the efficacy of buparvaquone against resistant visceral leishmaniasis."
01/01/2018 - "Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis."
07/01/2004 - "Novel oxime derivatives (2, 3 and 5) of buparvaquone (1) and O-methyl-buparvaquone (4) were synthesized and their in vitro activities against Leishmania donovani, the causative agent of visceral leishmaniasis (VL), were determined. "
01/01/2021 - "As the conclusion, the biogenic silicon nanoparticles are promising carriers to significantly improve the therapeutic efficacy and selectivity of buparvaquone against resistant visceral leishmaniasis opening a new avenue for low-cost treatment against this neglected tropical disease threatening especially the poor people in developing nations."